Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Keiichiro Uemura"'
Autor:
Kosuke Ueda, Keiichiro Uemura, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Sachiko Ogasawara, Hirohisa Yano, Tsukasa Igawa
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1701-1712 (2024)
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the exp
Externí odkaz:
https://doaj.org/article/11f53d13330b4e1285ae6a5190539e9a
Autor:
Hiroki Tsujioka, Keiichiro Uemura, Toshiyuki Iwahata, Yasuyuki Inoue, Minoru Inoue, Akiyoshi Osaka, Akinori Nakayama, Hiroshi Okada, Kazutaka Saito
Publikováno v:
IJU Case Reports, Vol 6, Iss 2, Pp 97-100 (2023)
Introduction Regressed germ cell tumors are a rare disease commonly diagnosed with metastatic symptoms without local symptoms in the testis. Case presentation A 33‐year‐old man with azoospermia was referred to our hospital. His right testis was s
Externí odkaz:
https://doaj.org/article/5a987561792b40d79873c1803cf4e05e
Autor:
Makoto Nakiri, Kosuke Ueda, Naoyuki Ogasawara, Hirofumi Kurose, Keiichiro Uemura, Kiyoaki Nishihara, Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Tsukasa Igawa
Publikováno v:
IJU Case Reports, Vol 5, Iss 4, Pp 223-226 (2022)
Introduction We present tri‐modality therapy with i‐125 brachytherapy for high‐risk prostate cancer after holmium laser enucleation of the prostate. Case presentation A 75‐year‐old man had visited our hospital with complaints of dysuria. Ho
Externí odkaz:
https://doaj.org/article/7d995e8092424a7cbb47a38feede0bbb
Autor:
Makoto Nakiri, Naoyuki Ogasawara, Hirofumi Kurose, Kosuke Ueda, Katsuaki Chikui, Kiyoaki Nishihara, Kazuhisa Ejima, Keiichiro Uemura, Kenta Murotani, Koichiro Muraki, Chikayuki Hattori, Etsuyo Ogo, Yoshitaka Morimatsu, Tatsuya Ishitake, Tsukasa Igawa
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 14, Iss 2, Pp 157-168 (2022)
Externí odkaz:
https://doaj.org/article/15782f7123944fda9ab40fe834136839
Autor:
Hiroki Tsujioka, Keiichiro Uemura, Toshiyuki Iwahata, Yasuyuki Inoue, Minoru Inoue, Akiyoshi Osaka, Akinori Nakayama, Hiroshi Okada, Kazutaka Saito
Publikováno v:
IJU Case Reports. 6:97-100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88f94b9d3326096ed627a3b789506551
https://doi.org/10.1002/iju5.12552
https://doi.org/10.1002/iju5.12552
Autor:
Kosuke Ueda, Naoyuki Ogasawara, Naoki Ito, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 6; Pages: 2417
Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ca23fd28891f3b17dc6fe84fd7005f
Autor:
Kosuke Ueda, Hirofumi Kurose, Makoto Nakiri, Katsuaki Chikui, Tsukasa Igawa, Shigetaka Suekane, Tasuku Hiroshige, Mitsunori Matsuo, Keiichiro Uemura, Kiyoaki Nishihara, Naoyuki Ogasawara
Publikováno v:
Japanese Journal of Clinical Oncology. 52:179-186
Objective Programmed cell death-1 antibody therapy has demonstrated improved progression-free survival and overall survival in patients with metastatic renal cell carcinoma. However, there are limited studies on biomarkers that can predict the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9a702d3c4c222c30d058b8fe090902
https://doi.org/10.1093/jjco/hyab157
https://doi.org/10.1093/jjco/hyab157
Autor:
KOSUKE UEDA, SHIGETAKA SUEKANE, HIROFUMI KUROSE, NAOKI ITO, NAOYUKI OGASAWARA, TASUKU HIROSHIGE, KATSUAKI CHIKUI, KAZUHISA EJIMA, KEIICHIRO UEMURA, MAKOTO NAKIRI, KIYOAKI NISHIHARA, MITSUNORI MATSUO, TSUKASA IGAWA
Publikováno v:
Anticancer research. 42(9)
Immuno-oncology (IO) combination therapy has become the standard of treatment for advanced renal cell carcinoma (RCC). In this retrospective study, we compared the efficacy of first-line molecular targeted therapy (MTT), administered as monotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa2bdc87fe0cf92d3a250d6b77785509
https://pubmed.ncbi.nlm.nih.gov/36039432
https://pubmed.ncbi.nlm.nih.gov/36039432
Autor:
Yoshihiro Matsunaga, Kiyoaki Nishihara, Naoyuki Ogasawara, Katsuaki Chikui, Shigetaka Suekane, Makoto Nakiri, Keiichiro Uemura, Satoru Yonekura, Hirofumi Kurose, Kosuke Ueda, Tsukasa Igawa, Ryuji Hoshino, Mitsunori Matsuo
Publikováno v:
Anticancer Research. 40:1739-1745
BACKGROUND/AIM The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795b3c7fee6351b058e11d96b949a029
https://doi.org/10.21873/anticanres.14127
https://doi.org/10.21873/anticanres.14127
Autor:
Kiyoaki Nishihara, Kosuke Ueda, Hirofumi Kurose, Naoyuki Ogasawara, Tasuku Hiroshige, Katsuaki Chikui, Kazuhisa Ejima, Keiichiro Uemura, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa
Publikováno v:
Oncol Lett
To analyze the risks and survival outcomes of non-definitive therapy (nDT) for muscle-invasive bladder cancer (MIBC), which may provide useful information for future treatment selection, the present study analyzed 124 patients who were diagnosed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e072e596059184849f4cbb021a2eba82
https://pubmed.ncbi.nlm.nih.gov/35261639
https://pubmed.ncbi.nlm.nih.gov/35261639